Spermidine for Hair Loss

Verdict: Weak, industry-only evidence; not a proven treatment

The evidence that spermidine supplements treat hair loss is weak: it rests on a single small manufacturer-funded oral trial plus mechanistic lab work, with no independent replication. It should not be considered a proven hair-loss treatment.

C 🟠 C Weak Evidence Taiwan Regulatory Restriction

🔬Why this grade7-layer evidence engine

This claim earns a Weak (C) grade because the human data are thin and conflicted. The only oral trial is Rinaldi 2017 (PMID 29214104), a 13-week double-blind RCT in 100 people that reported more anagen (growing) follicles and a negative pull test versus placebo. But it did not disclose the actual spermidine dose, and it was funded by the supplement's maker (Giuliani/Tricovel). The mechanistic rationale comes from a 2011 ex vivo study (PMID 21818338) showing spermidine prolongs anagen and raises stem-cell keratins K15/K19 in cultured follicles.

Crucially, every supporting study is industry-funded, and there has been no independent replication in roughly a decade. A second trial (PMID 29766701) tested a topical spermidine analogue, not the oral supplement itself, so it cannot confirm the pills work. This single-source, conflict-of-interest pattern is the main reason the grade stays low rather than moderate.

Regulators and clinicians reinforce the caution. EFSA reviewed the hair claims in 2011 and rejected them, finding no established cause-and-effect; its later authorization treats spermidine-rich wheat-germ extract only as a food capped at 6 mg/day, with no approved hair claim. The FDA stopped evaluating the relevant notice, and major clinical sources (NIH ODS, Mayo, Cleveland Clinic, Harvard, AAD/ISHRS) do not list spermidine for hair loss at all, instead pointing to proven options like minoxidil and finasteride.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.50
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Taiwan Regulatory Restriction
Confidence
47%
Conflicting evidence
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L11 AI re-checkIndependent read
0.50
L2 PubMedPrimary literature
0.60
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.503
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 1 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

A spermidine-based nutritional supplement prolongs the anagen phase of hair follicles in humans: a randomized, placebo-controlled, double-blind study
PMID: 29214104 2017 RCT (double-blind) n = 100
Finding: Treatment group showed significantly increased anagen V-VI HFs and Ki-67 with decreased c-Kit at 3 months vs placebo; pull test remained negative in all supplement recipients at 6 months vs 68% positive in placebo (exact p-values not in abstract).
⚠️ Industry-funded Effect size: ~17% increase in anagen phase (vendor-reported); raw between-group SMD not published
View on PubMed
New multi-targeting strategy in hair growth promotion: in vitro and in vivo studies (N1-methylspermidine + Sandalore topical lotion)
PMID: 29766701 2018 RCT (double-blind) n = 60
Finding: Statistically significant reduction in hair loss and increase in hair growth parameters at 3 months; benefits persisted 3 months post-treatment except wash test (specific p-values not in abstract).
⚠️ Industry-funded Effect size: Not reported numerically
View on PubMed
Spermidine promotes human hair growth and is a novel modulator of human epithelial stem cell functions
PMID: 21818338 2011 In vitro
Finding: Spermidine prolonged anagen, promoted hair shaft elongation, and upregulated epithelial stem cell keratins K15/K19 — mechanistic basis for oral Rinaldi 2017 trial.
⚠️ Industry-funded Effect size: Not applicable (mechanistic)
View on PubMed
Assessment of the effects of a hair lotion in women with acute telogen effluvium: a randomized controlled study
PMID: 34668237 2021 RCT (open-label) n = 100
Finding: Intervention reduced telogen density and hair shed (P=0.0465 W8, P=0.0392 W8 vs control); not a spermidine study.
🟠 Limited quality ⚠️ Industry-funded Effect size: Not reported
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Neutral
At the notifier's request, FDA ceased to evaluate this notice source↗
L4b EU EFSA
Cautious
Equivalent of max. 6 mg/day spermidine; Food supplements as defined in Directive 2002/46/EC, excluding food supplements for infants, young children, children, adolescents, pregnant and lactating women. The designation of the novel food on the labelling of the foodstuffs containing it shall be 'spermidine-rich wheat germ extract'. source↗
L4e WHO
Cautious
Spermidine [in Spermidine trihydrochloride] ... This ingredient cannot be used in natural health products without the submission of additional evidence for safety. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-hair-loss-INT-spermidine-001 繁體中文版 →